About this trial
The inflammatory bowel diseases (IBD) are described as complex, recurrent inflammatory conditions which are manifested as Crohn's disease (CD) and ulcerative colitis (UC). The common symptoms of IBD include debilitating/severe diarrhea, abdominal pain, weight loss, and chronic fatigue; events that may culminate in life-threatening complications. The pathogenesis of IBD has been characterized as complex/multi-factorial that includes disruption of intestinal epithelial barrier with consequent translocation of commensal microbial products as the prime event that instigates severe immune responses and intestinal inflammation.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Both male and female will be
Mild and moderate UC patients diagnosed and confirmed by endoscope
Disqualifiers
Breast feeding
Significant liver and kidney function abnormalities
Colorectal cancer patients
Patients with severe UC
Trial design
Treatments tested in this trial
- Mesalamine
- Dapagliflozin 10mg Tab
Treatment groups
Sponsors and collaborators
Mostafa Bahaa
Lead sponsor
Tanta University
Sponsor institution